Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TVTX

Travere Therapeutics Inc

Sep 15 • 04:00PM ET

23.01

-0.46 -1.96 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RARE SRPT VYGR FOLD QURE CRSP AGIO CLLS PFE

| Held by: IWM VTI XBI IWO VXF IBB PJP SCHA VTWO LFSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.04	Insider Own	2.67%	Shs Outstand	89.10M	Perf Week	8.54%
Market Cap	2.05B	Forward P/E	46.58	EPS next Y	0.49	Insider Trans	-1.35%	Shs Float	86.76M	Perf Month	26.22%
Enterprise Value	2.13B	PEG	-	EPS next Q	-0.27	Inst Own	115.78%	Short Float	13.93%	Perf Quarter	58.69%
Income	-169.06M	P/S	6.14	EPS this Y	72.79%	Inst Trans	2.51%	Short Ratio	6.51	Perf Half Y	16.62%
Sales	333.87M	P/B	62.61	EPS next Y	144.51%	ROA	-30.55%	Short Interest	12.08M	Perf YTD	32.09%
Book/sh	0.37	P/C	6.42	EPS next 5Y	-	ROE	-705.73%	52W High	28.69 -19.81%	Perf Year	87.99%
Cash/sh	3.58	P/FCF	-	EPS past 3/5Y	-10.63% -3.34%	ROIC	-47.24%	52W Low	12.57 83.05%	Perf 3Y	-15.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	0.83% 5.87%	Gross Margin	81.87%	Volatility	8.57% 6.10%	Perf 5Y	27.98%
Dividend TTM	-	EV/Sales	6.38	EPS Y/Y TTM	57.84%	Oper. Margin	-51.12%	ATR (14)	1.49	Perf 10Y	-13.53%
Dividend Ex-Date	-	Quick Ratio	1.98	Sales Y/Y TTM	87.94%	Profit Margin	-50.64%	RSI (14)	61.90	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	2.00	EPS Q/Q	84.22%	SMA20	15.17%	Beta	0.80	Target Price	36.50
Payout	-	Debt/Eq	12.20	Sales Q/Q	111.49%	SMA50	29.08%	Rel Volume	1.21	Prev Close	23.47
Employees	385	LT Debt/Eq	9.93	Earnings	Aug 06 AMC	SMA200	26.62%	Avg Volume	1.86M	Price	23.01
IPO	Oct 06, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	55.09% -4.65%	Trades		Volume	2,223,158	Change	-1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-25	Resumed	H.C. Wainwright	Buy	$30
Jun-11-25	Reiterated	Citigroup	Buy	$35 → $32
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$9 → $27
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy	$25
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30
Dec-14-22	Initiated	Stifel	Hold	$22
Dec-05-22	Initiated	Wells Fargo	Overweight	$28

Show Previous Ratings

Sep-12-25 01:16PM	Hims & Hers Leads 14 Growth Stocks Amid Medical Boom (Investor's Business Daily) -6.12%
Sep-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.46%
10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks)
09:15AM	Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside (Insider Monkey)
04:57AM	Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? (Zacks)
09:13AM	Loading…
Sep-10-25 09:13AM	Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High (Investor's Business Daily) +26.20%
11:17AM	Stock Market Today: Inflation Data Hits Dow; Oracle Soars As This Biotech Zooms (Live Coverage) (Investor's Business Daily)
07:01AM	Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI (sparsentan) in FSGS (Business Wire)
Sep-03-25 07:01AM	Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism (Business Wire) +8.04%
Aug-28-25 10:00AM	Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch (Investor's Business Daily)
Aug-27-25 05:09PM	Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI (sparsentan) in IgA Nephropathy (Business Wire)
Aug-17-25 11:41PM	Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts (Insider Monkey)
Aug-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-25 09:06AM	Travere Therapeutics price target raised to $32 from $30 at Wedbush (TipRanks)
Aug-06-25 06:00PM	Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings (Zacks)
05:15PM	Loading…
05:15PM	Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:13PM	Travere: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-05-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
09:54AM	Earnings To Watch: Travere Therapeutics Inc (TVTX) Reports Q2 2025 Result (GuruFocus.com)
Jul-31-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-30-25 04:30PM	Travere Therapeutics to Report Second Quarter 2025 Financial Results (Business Wire)
Jul-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-06-25 04:15AM	Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX) (Insider Monkey)
Jun-24-25 12:46PM	Travere Therapeutics Kicks Off "Play It Forward" Campaign for FSGS Awareness (Insider Monkey) +5.18%
Jun-13-25 02:02PM	HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs (Insider Monkey)
Jun-12-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-11-25 07:01AM	Travere Therapeutics to Present New FILSPARI (sparsentan) Data at the 15th International Podocyte Conference (Business Wire)
Jun-10-25 07:00AM	Travere Therapeutics Launches 'Play It Forward' Campaign to Celebrate the FSGS Community on Inaugural Awareness Day (Business Wire)
Jun-03-25 04:30PM	Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress (Business Wire)
04:00AM	Loading…
May-23-25 04:00AM	England's NICE recommends FILSPARI (sparsentan) as a treatment option for IgA nephropathy (PR Newswire)
May-15-25 04:05PM	Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI (sparsentan) in FSGS (Business Wire) -20.57%
May-13-25 04:05PM	Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results (GlobeNewswire)
May-12-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.59%
May-07-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
May-01-25 11:07PM	Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:30PM	Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Travere Therapeutics Reports First Quarter 2025 Financial Results (Business Wire)
Apr-29-25 07:01AM	Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy (Business Wire)
02:00AM	CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI in IgA Nephropathy (PR Newswire)
Apr-28-25 10:00AM	Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) +5.62%
Apr-24-25 04:30PM	Travere Therapeutics to Report First Quarter 2025 Financial Results (Business Wire) +5.57%
Apr-12-25 10:20AM	Travere Therapeutics price target lowered to $30 from $32 at Scotiabank (TipRanks)
Apr-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.49%
Apr-07-25 03:27AM	Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock? (Zacks)
Mar-31-25 04:30PM	Travere Therapeutics to Present New FILSPARI (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 (Business Wire) -8.94%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-26-25 09:39PM	Is Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
07:00AM	Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer (GlobeNewswire)
Mar-17-25 07:01AM	Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI (sparsentan) for the Treatment of FSGS (GlobeNewswire) +5.78%
Mar-12-25 05:30PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.32%
Feb-24-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Feb-23-25 03:03PM	Travere Therapeutics, Inc. (TVTX): the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-22-25 09:20AM	Travere Therapeutics price target raised to $30 from $24 at TD Cowen (TipRanks)
Feb-20-25 04:01PM	Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -6.79%
09:06AM	What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings (GuruFocus.com)
Feb-14-25 02:06PM	Travere Therapeutics (TVTX): Among The SmallCap Stocks Insiders Are Selling Recently (Insider Monkey)
Feb-13-25 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
10:31AM	Travere Therapeutics price target raised to $32 from $27 at Scotiabank (TipRanks)
Feb-12-25 05:30PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-11-25 07:01AM	Travere Therapeutics to Submit sNDA for FILSPARI (sparsentan) in FSGS (GlobeNewswire) +12.56%
Jan-13-25 07:00AM	Travere Therapeutics Provides Corporate Update and 2025 Outlook (GlobeNewswire)
Jan-06-25 04:30PM	Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-03-24 05:51AM	Japan MHLW grants orphan drug status to Renalys' sparsentan for IgAN treatment (Pharmaceutical Business Review)
Nov-25-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-13-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-12-24 04:05PM	Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Nov-07-24 09:05PM	Travere Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +12.40%
04:01PM	Travere Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-04-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-01-24 03:05AM	Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid ... (GuruFocus.com)
Oct-31-24 07:00AM	Travere Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 09:13AM	Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com)
Oct-28-24 08:35AM	Travere presents data reinforcing clinical benefit of FILSPARI in IgAN (TipRanks)
Oct-26-24 07:01AM	Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 (GlobeNewswire)
Oct-21-24 04:30PM	Travere Therapeutics to Report Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-17-24 07:01AM	Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (GlobeNewswire)
02:30AM	CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI (sparsentan) for the treatment of IgA Nephropathy (PR Newswire)
Oct-14-24 04:30PM	Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire) +6.28%
Oct-09-24 03:50PM	Travere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com) +15.65%
08:02AM	Travere Therapeutics, Inc. (TVTX) Increases R&D Investments Amidst Rising Product Sales (Insider Monkey)
Sep-26-24 04:01PM	Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up (GlobeNewswire) -6.85%
Sep-12-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.98%
Sep-10-24 04:01PM	Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-24 09:20AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Business Wire) +10.57%
Sep-05-24 05:34PM	Travere Therapeutics Announces Full FDA Approval of FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (GlobeNewswire)
Aug-22-24 04:30PM	Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024 (GlobeNewswire)
Aug-06-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -5.39%
Aug-01-24 04:01PM	Travere Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 04:30PM	Travere Therapeutics to Report Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-10-24 08:43AM	Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength? (Zacks)
Jul-08-24 04:30PM	Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference (GlobeNewswire) +10.52% +8.83%
Jun-24-24 07:32AM	Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar? (Zacks) +6.57%
Jun-11-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-09-24 04:30PM	Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress (GlobeNewswire)
May-08-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 03 '25	Sale	18.20	454	8,263	92,202	Sep 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 04 '25	Sale	19.71	119	2,345	92,083	Sep 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Aug 27 '25	Sale	17.31	470	8,136	92,656	Aug 28 04:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jul 01 '25	Sale	14.65	815	11,940	88,787	Jul 02 05:28 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	May 05 '25	Sale	21.05	1,784	37,553	93,126	May 05 09:54 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	May 05 '25	Sale	21.05	18,924	398,350	419,173	May 05 09:53 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	May 05 '25	Sale	21.05	1,771	37,280	128,215	May 05 09:53 PM
ROTE WILLIAM E.	Chief Research Officer	May 05 '25	Sale	21.05	3,198	67,318	100,241	May 05 09:52 PM
REED ELIZABETH E	Chief Legal Officer and GC	May 05 '25	Sale	21.05	4,920	103,566	89,482	May 05 09:51 PM
Christopher Cline	Officer	May 05 '25	Proposed Sale	21.05	1,784	37,553		May 05 07:45 PM
Peter Heerma	Officer	May 05 '25	Proposed Sale	21.05	1,771	37,280		May 05 07:41 PM
REED ELIZABETH E	Officer	May 05 '25	Proposed Sale	21.05	4,920	103,566		May 05 11:32 AM
Dube Eric M	Officer	May 05 '25	Proposed Sale	21.05	18,924	398,350		May 05 11:20 AM
ROTE WILLIAM E.	Officer	May 05 '25	Proposed Sale	21.05	3,198	67,318		May 05 10:08 AM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 11 '25	Sale	13.14	48	631	89,990	Apr 14 06:23 PM
Christopher Cline	Officer	Apr 11 '25	Proposed Sale	13.14	48	631		Apr 11 07:03 PM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Feb 12 '25	Sale	23.53	5,200	122,356	98,519	Feb 12 09:30 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Feb 12 '25	Sale	23.53	8,000	188,240	89,482	Feb 12 09:28 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 11 '25	Option Exercise	16.63	45,000	748,200	78,654	Feb 12 09:27 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 11 '25	Sale	25.00	54,244	1,356,100	54,410	Feb 12 09:27 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 11 '25	Sale	25.00	3,074	76,850	127,634	Feb 12 09:25 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 12 '25	Sale	23.53	2,568	60,426	125,066	Feb 12 09:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 11 '25	Sale	24.04	11,375	273,455	419,173	Feb 12 09:23 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 12 '25	Sale	23.53	2,568	60,426	89,602	Feb 12 09:22 PM
Peter Heerma	Officer	Feb 12 '25	Proposed Sale	23.53	2,568	60,426		Feb 12 07:47 PM
Jula Inrig	Officer	Feb 12 '25	Proposed Sale	23.53	2,568	60,426		Feb 12 07:46 PM
ROTE WILLIAM E.	Officer	Feb 12 '25	Proposed Sale	23.53	5,200	122,356		Feb 12 11:03 AM
REED ELIZABETH E	Officer	Feb 12 '25	Proposed Sale	23.53	8,000	188,240		Feb 12 09:52 AM
SANDRA CALVIN	Officer	Feb 11 '25	Proposed Sale	25.00	54,244	1,356,100		Feb 11 04:08 PM
PETER HEERMA	Officer	Feb 11 '25	Proposed Sale	25.00	3,074	76,850		Feb 11 04:04 PM
Dube Eric M	Officer	Feb 11 '25	Proposed Sale	24.04	11,375	273,455		Feb 11 11:56 AM
Baynes Roy D.	Director	Feb 06 '25	Option Exercise	17.44	10,000	174,400	41,000	Feb 10 06:04 PM
Baynes Roy D.	Director	Feb 06 '25	Sale	22.00	10,000	220,000	31,000	Feb 10 06:04 PM
ROY D BAYNES	Director	Feb 06 '25	Proposed Sale	22.00	10,000	220,000		Feb 06 04:21 PM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Feb 03 '25	Sale	19.78	8,951	177,051	95,719	Feb 04 08:30 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Feb 03 '25	Sale	19.78	8,951	177,051	89,482	Feb 04 08:30 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 03 '25	Sale	20.21	50,691	1,024,343	430,548	Feb 04 08:30 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 03 '25	Sale	20.12	4,207	84,645	85,236	Feb 04 08:30 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 04 '25	Sale	20.11	1,066	21,437	84,170	Feb 04 08:30 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 03 '25	Sale	20.12	5,166	103,940	122,708	Feb 04 08:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 03 '25	Sale	20.12	5,192	104,463	90,038	Feb 04 08:30 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 03 '25	Sale	20.12	3,348	67,362	63,654	Feb 04 08:30 PM
JULA INRIG	Officer	Feb 04 '25	Proposed Sale	20.11	1,066	21,437		Feb 04 04:11 PM
Peter Heerma	Officer	Feb 03 '25	Proposed Sale	20.12	5,166	103,934		Feb 03 08:47 PM
Christopher Cline	Officer	Feb 03 '25	Proposed Sale	20.12	5,192	104,457		Feb 03 08:46 PM
Sandra Calvin	Officer	Feb 03 '25	Proposed Sale	20.12	3,348	67,358		Feb 03 08:41 PM
Jula Inrig	Officer	Feb 03 '25	Proposed Sale	20.12	4,207	84,640		Feb 03 08:40 PM
REED ELIZABETH E	Officer	Feb 03 '25	Proposed Sale	19.78	8,951	177,051		Feb 03 12:26 PM
Dube Eric M	Officer	Feb 03 '25	Proposed Sale	19.78	50,691	1,002,668		Feb 03 11:22 AM
ROTE WILLIAM E.	Officer	Feb 03 '25	Proposed Sale	19.78	8,951	177,051		Feb 03 11:11 AM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Jan 22 '25	Sale	19.46	2,437	47,424	83,170	Jan 23 08:40 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 22 '25	Sale	19.46	10,736	208,923	351,239	Jan 23 08:39 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Jan 22 '25	Sale	19.46	2,437	47,424	76,933	Jan 23 08:37 PM
Baynes Roy D.	Director	Jan 23 '25	Option Exercise	17.50	16,000	280,000	47,000	Jan 23 08:36 PM
Baynes Roy D.	Director	Jan 23 '25	Sale	20.00	16,000	320,000	31,000	Jan 23 08:36 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Jan 22 '25	Sale	18.94	1,584	30,002	106,374	Jan 23 08:35 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Jan 22 '25	Sale	18.94	865	16,384	73,730	Jan 23 08:33 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Jan 22 '25	Sale	18.94	925	17,520	54,002	Jan 23 08:31 PM
ROY D BAYNES	Director	Jan 23 '25	Proposed Sale	20.00	16,000	320,000		Jan 23 04:14 PM
Dube Eric M	Officer	Jan 22 '25	Proposed Sale	19.46	10,736	208,923		Jan 22 10:34 AM
REED ELIZABETH E	Officer	Jan 22 '25	Proposed Sale	19.46	2,437	47,424		Jan 22 10:18 AM
ROTE WILLIAM E.	Officer	Jan 22 '25	Proposed Sale	19.46	2,437	47,424		Jan 22 09:36 AM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 03 '25	Sale	19.10	2,066	39,461	59,883	Jan 06 07:21 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 06 '25	Sale	18.76	440	8,254	59,443	Jan 06 07:21 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 26 '24	Option Exercise	12.67	15,000	190,050	69,927	Dec 27 07:47 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 26 '24	Sale	17.22	15,000	258,277	54,927	Dec 27 07:47 PM
SANDRA CALVIN	Officer	Dec 26 '24	Proposed Sale	17.22	15,000	258,278		Dec 26 04:13 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 25 '24	Option Exercise	12.67	15,000	190,050	67,017	Nov 25 09:00 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 25 '24	Sale	18.30	12,090	221,258	54,927	Nov 25 09:00 PM
Calvin Sandra	Officer	Nov 25 '24	Proposed Sale	18.30	12,090	221,258		Nov 25 05:59 PM
LYONS GARY A	Director	Oct 04 '24	Option Exercise	10.48	40,000	419,200	91,000	Oct 04 07:15 PM
LYONS GARY A	Director	Oct 04 '24	Sale	14.73	40,000	589,101	51,000	Oct 04 07:15 PM
GARY A LYONS	Officer	Oct 04 '24	Proposed Sale	13.65	40,000	546,000		Oct 04 04:21 PM
Meckler Jeffrey A	Director	Sep 30 '24	Option Exercise	10.48	40,000	419,200	121,000	Sep 30 08:38 PM
Meckler Jeffrey A	Director	Sep 30 '24	Sale	14.06	40,000	562,324	81,000	Sep 30 08:38 PM
JEFFREY MECKLER	Director	Sep 30 '24	Proposed Sale	14.06	40,000	562,324		Sep 30 04:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TVTX

Travere Therapeutics Inc

Upgrade your FINVIZ experience